Two Decades of Synthesis
Over 20 years of China-based peptide production: SPPS scale-up, cleanroom lyophilization, and batch QC built for laboratories and institutional buyers — not anonymous grey-market resellers.
Research Use Only — Not For Human Consumption
Documented GLP-1 Research Peptides forMetabolic & EndocrineLaboratories
When public sequences meet inconsistent grey-market quality, assays fail. PeptideLab supplies HPLC-verified retatrutide, tirzepatide, and semaglutide lyophilized RUO material — with COA-backed identity for incretin pathway and metabolic research models.
↓ Scroll for interactive product showcase
Manufacturing & Distribution
20 Years of Peptide Production in China — Plus Authorized Lilly Supply
We manufacture research-grade peptides in-house and operate an authorized channel for genuine Eli Lilly (Japan) pharmaceutical products. Every lot — custom synthesis or branded authentic — is open to independent third-party testing.
Authorized Lilly Authentic Line
Authorized channel for genuine Eli Lilly (Japan) pharmaceutical products — Mounjaro® (tirzepatide) and related Lilly SKUs in our Lilly Authentic catalog, plus other Japan-sourced authentic metabolic medicines. Genuine product, not replicas.
Third-Party Verification Welcome
Send any batch to Janoshik, ChemClarity, or your own accredited lab. We support HPLC, mass spec, and pharmaceutical authenticity checks — and stand behind the results.
Lilly Authentic products are genuine pharmaceutical goods. Research peptides are sold strictly as Research Use Only (RUO) and are not for human consumption.
Scroll to explore · HPLC Verified
Laboratory-Grade Peptide Architecture
Scroll lightly to rotate the vial and preview featured compounds.
RUO
Scroll progress
GMP-Compliant Facility
Direct from GMP-Compliant Synthesis Labs
99.9% Purity • HPLC Tested • Lyophilized in Sterile Environments
What Research Labs Need — And What Grey-Market Supply Often Misses
Public peptide sequences do not guarantee batch identity, purity, or stability. We help qualified teams close that gap with documented analytics.
Reproducible metabolic assays
Menopause-adjacent models often show shifted fat distribution, insulin resistance, and visceral adiposity markers. GLP-1 / GIP / glucagon pathway tools need consistent lot potency so week-to-week readouts stay comparable.
Identity you can defend in a paper
For triple agonists such as retatrutide, sequence information is disclosed in patents and trial literature — but synthesis route, side-chain lipidation, and impurities differ by supplier. Mass spec + HPLC on every batch supports institutional procurement.
RUO compliance built in
Explicit Research Use Only labeling, COA on request, and no human-use dosing guidance. Materials are for in-vitro and qualified preclinical workflows under your IRB / IACUC — not pharmacy substitutes.
Metabolic & endocrine research
Studying Post-Menopausal Metabolic Shift — At the Bench
Clinical literature describes a surge in GLP-1–class interest among women around 50–64 — driven primarily by health: estrogen decline, abdominal adiposity, and cardiovascular risk markers — not cosmetic goals alone. Laboratories model these pathways with controlled peptide tools.
Visceral adiposity & insulin signaling
Incretin agonists are used in cell and animal models to probe appetite circuits, hepatic lipid handling, and insulin sensitivity — relevant to peri- and post-menopausal metabolic phenotypes cited in epidemiology.
Triple vs dual agonist design
Retatrutide (GLP-1 + GIP + glucagon) and tirzepatide (GLP-1 + GIP) let teams compare receptor coverage and energy-expenditure endpoints in parallel arms — with matched lyophilized strengths and COA-backed identity.
Combination research contexts
Published work explores hormone-replacement and incretin-pathway interactions in weight and body-composition outcomes. We supply reference-grade RUO material; study design and combinations remain your protocol decision.
Transparency & quality
Why Retatrutide Sequence Is Public — And Why Labs Still Need a Trusted Lot
Public sequence ≠ pharmaceutical equivalence
Retatrutide is a 39–amino acid engineered peptide (GIP backbone with defined non-natural residues and side-chain lipidation) described in Eli Lilly patent literature (e.g. US11542313B2) and peer-reviewed trial reports. Disclosure supports patent examination and scientific reproducibility — similar to other incretin peptides.
View Retatrutide Specifications- Structure disclosure
- Patents and trial publications define sequence motifs and modifications (e.g. Aib, α-MeLeu, fatty-acid conjugation). That enables SPPS suppliers worldwide — but not interchangeable pharmaceutical quality.
- What “generic” material misses
- Impurity profiles, oxidation, wrong lipidation, and water content drive assay failure. Grey-market “research chemical” labels do not replace COA, MS identity, or stability data.
- Our role
- PeptideLab ships lyophilized RUO retatrutide with HPLC purity reporting and optional COA — for qualified laboratories only. Not Lilly’s investigational product; not for human injection or weight-loss treatment.
- Compound and use patents may apply in your jurisdiction — verify legal use before import.
- Investigational agents are not approved medicines; wait for regulated products for patient care.
Why Laboratories Choose Documented Supply
Batch analytics, sterile lyophilization, and compliance-first labeling — so your team can qualify lots for procurement, protocols, and publication.
HPLC & Mass Spec on Every Lot
Identity confirmation and purity reporting for institutional procurement. COA available with batch traceability.
Sterile Lyophilization
Cleanroom-aligned handling for sensitive incretin peptides — stability-focused packaging for laboratory storage.
Science-Referenced Resources
We cite public patent and trial literature so your team understands what RUO material is — and is not.
RUO & Compliance First
Not for human consumption, injection, weight-loss treatment, or pharmacy substitution.
Featured Research Compounds
Triple and dual incretin agonists plus established repair peptides — matched catalog tiers for parallel study arms.
Scientific review: PeptideLab analytical & compliance team
May 2026. Content aligned to RUO procurement standards, third-party testing workflows, and publicly cited patent / trial literature.
Research FAQ
Procurement, quality, and compliance for laboratory buyers
RUOcompliance
Medical disclaimer: This site educates qualified researchers and procurement officers. It does not provide diagnosis, prescribing, or personal weight-management advice. GLP-1 class peptides here are Research Use Only.
Legal & safety notice: Investigational compounds such as retatrutide remain under patent and regulatory review in many regions. Grey-market material may carry impurities and legal exposure. Use regulated medicines through licensed clinicians for patient care.